These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Exogenous interleukin 2 recruits in vitro lymphokine-activated killer activity by in vivo activated lymphocytes. Lamers HJ; Gratama JW; van Putten WL; Stoter G; Bolhuis RL Cancer Res; 1991 May; 51(9):2324-8. PubMed ID: 2015597 [TBL] [Abstract][Full Text] [Related]
13. Enhancement of murine lymphokine-activated killer cell activity by retinoic acid. Lin TH; Chu TM Cancer Res; 1990 May; 50(10):3013-8. PubMed ID: 1970751 [TBL] [Abstract][Full Text] [Related]
14. Prolongation of serum half-life of interleukin 2 and augmentation of lymphokine-activated killer cell activity by pepstatin in mice. Ohnishi H; Lin KM; Chu TM Cancer Res; 1990 Feb; 50(4):1107-12. PubMed ID: 2297759 [TBL] [Abstract][Full Text] [Related]
15. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors. Mulé JJ; Krosnick JA; Rosenberg SA J Immunol; 1989 Jan; 142(2):726-33. PubMed ID: 2783444 [TBL] [Abstract][Full Text] [Related]
16. Anti-candidial activity of natural killer (NK) and lymphokine activated killer (LAK) lymphocytes in vitro. Gülay Z; Imir T Immunobiology; 1996 Jul; 195(2):220-30. PubMed ID: 8877398 [TBL] [Abstract][Full Text] [Related]
17. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells. Kalland T; Belfrage H; Bhiladvala P; Hedlund G J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566 [TBL] [Abstract][Full Text] [Related]
18. Generation and characterization of purified adherent lymphokine-activated killer cells in mice. Gunji Y; Vujanovic NL; Hiserodt JC; Herberman RB; Gorelik E J Immunol; 1989 Mar; 142(5):1748-54. PubMed ID: 2783950 [TBL] [Abstract][Full Text] [Related]
19. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity. Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715 [TBL] [Abstract][Full Text] [Related]
20. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation. Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]